(STMN) Straumann Holding - Ratings and Ratios
Dental Implants, Orthodontic Aligners, Biomaterials, CADCAM Prosthetics, Digital
STMN EPS (Earnings per Share)
STMN Revenue
Description: STMN Straumann Holding
Straumann Holding AG is a leading global provider of tooth replacement and orthodontic solutions, offering a comprehensive range of products and services, including dental implants, CADCAM prosthetics, orthodontic aligners, biomaterials, and digital solutions. The companys diverse product portfolio caters to the needs of general dentists, specialists, and dental technicians, and is distributed through a network of subsidiaries, partners, and third-party distributors.
From a financial perspective, Straumann Holding AG has demonstrated strong performance, with a market capitalization of approximately 16.9 billion CHF. The companys return on equity (RoE) stands at 32.71%, indicating a high level of profitability. Additionally, the forward price-to-earnings (P/E) ratio is 29.76, suggesting that the stock may be reasonably valued relative to its expected earnings growth.
Some key performance indicators (KPIs) that may be relevant to evaluating Straumann Holding AGs performance include revenue growth, gross margin, and research and development (R&D) expenditure as a percentage of sales. The companys ability to maintain its market share and expand its presence in key markets, such as Europe and North America, will also be crucial to its long-term success. Furthermore, the growing demand for dental implants and orthodontic solutions, driven by an aging population and increasing awareness of oral health, is likely to support the companys growth prospects.
In terms of its competitive position, Straumann Holding AG operates in a highly competitive market, with other major players including Nobel Biocare, Zimmer Biomet, and Align Technology. However, the companys strong brand reputation, commitment to innovation, and extensive distribution network are likely to remain key competitive advantages. To maintain its leadership position, Straumann will need to continue investing in R&D and expanding its product offerings to meet evolving customer needs.
Additional Sources for STMN Stock
STMN Stock Overview
Market Cap in USD | 21,538m |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception |
STMN Stock Ratings
Growth Rating | -9.29 |
Fundamental | 59.5 |
Dividend Rating | 55.9 |
Rel. Strength | 4.24 |
Analysts | - |
Fair Price Momentum | 82.59 CHF |
Fair Price DCF | 29.74 CHF |
STMN Dividends
Dividend Yield 12m | 0.89% |
Yield on Cost 5y | 1.07% |
Annual Growth 5y | 8.13% |
Payout Consistency | 98.3% |
Payout Ratio | 18.2% |
STMN Growth Ratios
Growth Correlation 3m | -20.3% |
Growth Correlation 12m | -63.7% |
Growth Correlation 5y | 0% |
CAGR 5y | 2.28% |
CAGR/Max DD 5y | 0.04 |
Sharpe Ratio 12m | -0.88 |
Alpha | -29.32 |
Beta | 1.155 |
Volatility | 29.49% |
Current Volume | 0k |
Average Volume 20d | 201.9k |
Stop Loss | 96.2 (-3%) |
As of August 02, 2025, the stock is trading at CHF 99.14 with a total of 0 shares traded.
Over the past week, the price has changed by -9.34%, over one month by -5.17%, over three months by -5.08% and over the past year by -8.34%.
Partly, yes. Based on ValueRay´s Fundamental Analyses, Straumann Holding (SW:STMN) is currently (August 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 59.52 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of STMN is around 82.59 CHF . This means that STMN is currently overvalued and has a potential downside of -16.69%.
Straumann Holding has no consensus analysts rating.
According to our own proprietary Forecast Model, STMN Straumann Holding will be worth about 99.1 in August 2026. The stock is currently trading at 99.14. This means that the stock has a potential downside of -0.03%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 125 | 26.1% |
Analysts Target Price | - | - |
ValueRay Target Price | 99.1 | -0% |